Viking Therapeutics, Inc. (0VQA.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Viking Therapeutics, Inc.
Address
9920 Pacific Heights Boulevard
San Diego, CA 92121
United States of America (the)
Phone
858 704 4660
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
October 08, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Brian Lian | President, Chief Executive Officer & Director | 1.05M | 1966 |
| Michael Morneau | Vice President of Finance & Administration | 375,333 | 1965 |
| Gregory S. Zante | Chief Financial Officer | 738,000 | 1971 |
| Marianne Mancini | Chief Operating Officer | 765,000 | 1965 |
| Hubert C. Chen | Chief Medical Officer | 0 | 1969 |
| Kenneth Herman | Senior Vice President of Commercial, Marketing & Sales | 0 | N/A |
| Neil Aubuchon | Chief Commercial Officer | 0 | 1971 |
| Katherine Mercier | Vice President of Quality and Compliance | 0 | N/A |
| Geoffrey E. Barker | Chief Development Officer | 0 | N/A |
| Nils U. Olsson | Senior Vice President of Technical Operations | 0 | N/A |
Description
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to developing innovative therapies for metabolic and endocrine disorders. Its flagship product candidate, VK2809, is an orally administered, tissue- and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Currently, VK2809 is undergoing Phase IIb clinical trials to address non-alcoholic steatohepatitis (NASH) confirmed by biopsy, as well as non-alcoholic fatty liver disease (NAFLD). The company's pipeline further features VK5211, an orally available non-steroidal selective androgen receptor modulator, which is in Phase II trials for patients convalescing from non-elective hip fracture surgery. Additionally, VK0612, an oral candidate poised for Phase IIb evaluation, targets type 2 diabetes. Lastly, VK0214, another orally administered TRß selective agonist, is being developed for X-linked adrenoleukodystrophy. Established in 2012, Viking Therapeutics maintains its corporate headquarters in San Diego, California.
